Welcome to our dedicated page for Amedisys SEC filings (Ticker: AMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Complex Medicare reimbursement tables, shifting hospice regulations, and acquisition footnotes can make Amedisys, Inc. (NASDAQ: AMED) filings feel like a maze. If you have ever asked, “How do I locate the labor-cost breakout in Amedisys’ annual report 10-K?” or “Where are Amedisys insider trading Form 4 transactions listed in real time?”, this page is built for you.
Stock Titan’s AI-powered engine turns every AMED disclosure—10-K, 10-Q, 8-K, DEF 14A, S-8, and more—into clear, searchable insights. Our algorithms read the footnotes so you can quickly:
- Track clinician head-count trends inside the latest Amedisys quarterly earnings report 10-Q filing.
- Review hospice cap exposure highlighted in the Amedisys annual report 10-K simplified.
- Receive instant alerts for every Amedisys Form 4 insider transactions real-time, including executive stock sales ahead of rate-setting announcements.
- See board-level pay packages with a single click in the Amedisys proxy statement executive compensation.
Each document includes an AI summary that explains material events, from acquisition-related goodwill in an 8-K to segment margin shifts buried deep in MD&A. No more skimming hundreds of pages—our expert analysis highlights reimbursement changes, patient-census data, and cash-flow details investors use to benchmark post-acute providers.
Whether you’re comparing home-health operators or trying to understand “Amedisys insider trading Form 4 transactions”, this hub delivers every filing the moment it hits EDGAR, already decoded. Spend your time making decisions, not finding disclosures.
Compass Minerals International, Inc. (CMP) filed a Form 4/A to correct a duplicate insider filing made on 1 July 2025. The amendment re-affirms that Director Joseph E. Reece received 2,209 deferred stock units on 30 June 2025 at a grant price of $0 as part of standard board compensation. Following the grant, Reece now directly owns 65,755 CMP shares and indirectly holds 21,000 shares via a trust. No derivative securities were involved and there are no changes to the underlying transaction details; the sole purpose of the Form 4/A is to replace an inadvertently duplicated submission.
The disclosure is routine, reflects non-cash compensation, and does not signal any strategic shift or financial impact for CMP.
Rubrik, Inc. (RBRK) has filed a Form 144 indicating that an affiliate intends to sell up to 16,984 Class A shares through Merrill Lynch on or after 06/30/2025. The proposed transaction has an aggregate market value of $1.52 million and represents roughly 0.014% of the company’s 123.6 million shares outstanding, suggesting limited market impact. The shares were originally acquired in a private placement on 01/27/2014 for cash. The filing also lists prior sales over the past three months by related Lightspeed entities totaling 46,269 shares for $3.71 million in gross proceeds. The signatory attests that no undisclosed material adverse information is known.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What core services does Amedisys Inc provide?
How does Amedisys ensure personalized care for its patients?
What differentiates Amedisys from traditional healthcare providers?
How does Amedisys coordinate care with other healthcare providers?
What role does technology play in Amedisys' care delivery model?
How does the high acuity care segment operate?
Can Amedisys' care services help reduce hospital readmissions?
What is the market significance of Amedisys Inc in the healthcare industry?
